Patient and AML characteristics according to type of combination treatment received, either a DNMTi (azacitidine or decitabine) or LDAC with venetoclax
| . | Overall cohort (n = 81) . | VEN + DNMTi (n = 58) . | VEN + LDAC (n = 23) . |
|---|---|---|---|
| Age (y), median (range) | 74 (62–87) | 74 (62–87) | 73 (66–78) |
| Sex (male), % | 54 | 55 | 52 |
| Performance status, n (%) | |||
| 0 | 17 (21.0) | 7 (12.1) | 10 (43.5) |
| 1 | 54 (66.7) | 41 (70.7) | 13 (56.5) |
| 2 | 10 (12.3) | 10 (17.2) | — |
| Secondary AML, n (%) | 27 (33.3) | 17 (29.3) | 10 (43.5) |
| Prior DNMTi, n (%) | 5 (6.3) | — | 5 (21.7) |
| Cytogenetic risk, n (%) | |||
| Favorable | 1 (1.2) | — | 1 (4.3) |
| Intermediate | 50 (61.7) | 36 (62.1) | 14 (60.9) |
| Adverse | 26 (32.1) | 20 (34.5) | 6 (26.1) |
| Unknown | 4 (4.9) | 2 (3.4) | 2 (8.7) |
| Gene mutation, n* | 80 | 57 | 23 |
| SRSF2, n (%) | 17/39 (43) | 7/17 (41) | 10 (43) |
| TET2, n (%) | 19/79 (24) | 14 (25) | 5/22 (23) |
| ASXL1, n (%) | 19/79 (24) | 14 (25) | 5/22 (23) |
| STAG2, n (%) | 9/38 (24) | 4/16 (25) | 5/22 (23) |
| RUNX1, n (%) | 18/79 (23) | 9 (16) | 9/22 (41) |
| TP53, n (%) | 18/79 (23) | 14 (25) | 4/22 (18) |
| DNMT3A, n (%) | 16 (20) | 12 (21) | 4 (17) |
| NPM1, n (%) | 16 (20) | 12 (21) | 3 (13) |
| K/NRAS, n (%) | 15 (19) | 14 (25) | 1 (4) |
| IDH2, n (%) | 11 (14) | 8 (14) | 3 (13) |
| IDH1, n (%) | 11 (14) | 7 (12) | 4 (17) |
| FLT3-ITD, n (%) | 7 (9) | 5 (9) | 2 (9) |
| Response | |||
| (CR + CRi), % | 64 | 69 | 52 |
| CR, n (%) | 35 (43.2) | 23 (39.7) | 12 (52.2) |
| CRi, n (%) | 17 (21.0) | 17 (29.3) | — |
| MLFS, n (%) | 7 (8.6) | 4 (6.9) | 3 (13.0) |
| Refractory disease, n (%) | 20 (24.7) | 13 (22.4) | 7 (30.4) |
| Not evaluable, n (%) | 2 (2.5) | 1 (1.7) | 1 (4.3) |
| . | Overall cohort (n = 81) . | VEN + DNMTi (n = 58) . | VEN + LDAC (n = 23) . |
|---|---|---|---|
| Age (y), median (range) | 74 (62–87) | 74 (62–87) | 73 (66–78) |
| Sex (male), % | 54 | 55 | 52 |
| Performance status, n (%) | |||
| 0 | 17 (21.0) | 7 (12.1) | 10 (43.5) |
| 1 | 54 (66.7) | 41 (70.7) | 13 (56.5) |
| 2 | 10 (12.3) | 10 (17.2) | — |
| Secondary AML, n (%) | 27 (33.3) | 17 (29.3) | 10 (43.5) |
| Prior DNMTi, n (%) | 5 (6.3) | — | 5 (21.7) |
| Cytogenetic risk, n (%) | |||
| Favorable | 1 (1.2) | — | 1 (4.3) |
| Intermediate | 50 (61.7) | 36 (62.1) | 14 (60.9) |
| Adverse | 26 (32.1) | 20 (34.5) | 6 (26.1) |
| Unknown | 4 (4.9) | 2 (3.4) | 2 (8.7) |
| Gene mutation, n* | 80 | 57 | 23 |
| SRSF2, n (%) | 17/39 (43) | 7/17 (41) | 10 (43) |
| TET2, n (%) | 19/79 (24) | 14 (25) | 5/22 (23) |
| ASXL1, n (%) | 19/79 (24) | 14 (25) | 5/22 (23) |
| STAG2, n (%) | 9/38 (24) | 4/16 (25) | 5/22 (23) |
| RUNX1, n (%) | 18/79 (23) | 9 (16) | 9/22 (41) |
| TP53, n (%) | 18/79 (23) | 14 (25) | 4/22 (18) |
| DNMT3A, n (%) | 16 (20) | 12 (21) | 4 (17) |
| NPM1, n (%) | 16 (20) | 12 (21) | 3 (13) |
| K/NRAS, n (%) | 15 (19) | 14 (25) | 1 (4) |
| IDH2, n (%) | 11 (14) | 8 (14) | 3 (13) |
| IDH1, n (%) | 11 (14) | 7 (12) | 4 (17) |
| FLT3-ITD, n (%) | 7 (9) | 5 (9) | 2 (9) |
| Response | |||
| (CR + CRi), % | 64 | 69 | 52 |
| CR, n (%) | 35 (43.2) | 23 (39.7) | 12 (52.2) |
| CRi, n (%) | 17 (21.0) | 17 (29.3) | — |
| MLFS, n (%) | 7 (8.6) | 4 (6.9) | 3 (13.0) |
| Refractory disease, n (%) | 20 (24.7) | 13 (22.4) | 7 (30.4) |
| Not evaluable, n (%) | 2 (2.5) | 1 (1.7) | 1 (4.3) |
VEN, venetoclax.
One patient had no baseline molecular evaluation. If a denominator is not specified, all patients were tested for the gene mutation.